Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00429936

Enrollment

245

Registered

2007-02-01

Start date

2006-12-31

Completion date

2010-05-31

Last updated

2010-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Age Related Macular Degeneration, Geographic Atrophy

Keywords

Dry Age Related Macular Degeneration, Geographic Atrophy

Brief summary

The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).

Interventions

DRUGFenretinide

Once daily 30 minutes after the evening meal for 24 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

50 Years to 89 Years

Healthy volunteers

Inclusion criteria

* males or females, 50 to 89 years of age * must have GA from AMD in one or both eyes

Exclusion criteria

* GA due to any disease other than AMD (eg, drug-induced)

Design outcomes

Primary

Measure	Time frame
GA lesion progression	1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026